Biotek-snakken — Marts 2025
-
Ugens grafik 02: Investorerne forlader stadig biotek https://proinvestor.com/investornyt/1296485/ugens-grafik-02-investorerne-forlader-stadig-biotek
-
IBT is granted Breakthrough Therapy Designation for its Drug Candidate
-
"The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy designation for IBP-9414’s potential to reduce gastrointestinal-related mortality. A breakthrough designation is intended to facilitate and expedite the development and review of new drugs that address unmet medical needs in treating a serious or life-threatening condition."
-
"Generelt set forbedrer tildelingen af en "Breakthrough Therapy Designation" sandsynligheden for, at et lægemiddel opnår endelig godkendelse fra FDA. Studier har vist, at cirka 66% af de lægemidler, der har modtaget denne betegnelse, rent faktisk går videre til FDA-godkendelse. ..
-
""Breakthrough Therapy Designation" er derfor et stærkt positivt tegn på et lægemiddels potentiale. Den endelige godkendelse afhænger dog stadig af, at de afsluttende kliniske studier leverer robuste data, og at FDA foretager en positiv vurdering af både lægemidlets effekt og dets risikoprofil."
-
Infant Bacterial Therapeutics: 02 Sep 2024; SEB har købsanbefaling og et kursmål på 330 SEK (450 SEK). Infant Bacterial Therapeutics lukkede i kurs 37,3 SEK i fredags.
4. september 2024 09:34; SEB: IBT:s telefonkonferens positiv för oddsen att IBP-9414 blir godkänd (R) //Finwire.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind